-
GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript
28 Mar 2024 15:22 GMT
… Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript March 27, 2024 … Q4 and Full Year 2023 Earnings Call. At this time, … than double when considering the frontline AML market. Our important … Venetoclax in elderly patients with frontline AML. In addition, a …
-
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript
28 Mar 2024 15:21 GMT
… , Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript March 27, 2024 … to Cellectar Biosciences 2023 Yearend Earnings Call. Today’s call is … clinical development of Iopofosine, including frontline treatment of WM, WM treatment …
-
Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript
27 Mar 2024 16:02 GMT
… Inc. (NASDAQ:SYRS) Q4 2023 Earnings Conference Call March 27, 2024 … standard of care, for the frontline treatment of hematologic malignancies. … agent to improve the frontline treatment of higher-risk … of care in the frontline treatment of AML patients …
-
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
27 Mar 2024 05:53 GMT
… . (NASDAQ:OSA) Q4 2023 Earnings Conference Call March 27, 2024 … to the ProSomnus Q4 2023 Earnings Investors Update. At this … Preliminary data readout from the frontline OSA therapy study, a … in Brazil, reported that frontline treatment with ProSomnus EVO devices …
-
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
27 Mar 2024 00:45 GMT
… (NASDAQ:APTO) Q4 2023 Earnings Conference Call March 26, … triplet pilot study in frontline newly diagnosed AML patients … resources towards the frontline because frontline is going to … this pilot triplet study frontline because tuspetinib really differentiates …
-
ArriVent BioPharma Reports Full Year 2023 Financial Results
28 Mar 2024 20:05 GMT
Company progresses the development of furmonertinib with a data readout planned for 2024
Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration
Completed $201 million initial public offering (“IPO”) in January 2024
…
-
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26 Mar 2024 20:01 GMT
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML
Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile
Luxeptinib G3 Formulation Achieves Desired Levels and Positions for Future Trials
Conference Call …
-
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
25 Mar 2024 20:01 GMT
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024
Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort …
-
IMUNON Reports 2023 Financial Results and Provides Business Update
28 Mar 2024 12:00 GMT
… ;IV ovarian cancer. Patients undergoing frontline neoadjuvant therapy will be randomized … ask for the IMUNON 2023 Earnings Call. A live webcast of …
-
‘Stolen Time’ doc shows grim reality in some long-term care homes
27 Mar 2024 21:42 GMT
… .1 billion in revenue. Total earnings were $91 million. Cash dividends … includes the voices of families, frontline caregivers and change-makers as …